Abstract
The TEL/PDGFR beta (T/P) fusion protein isolated from patients bearing a t(5;12) translocation is transforming when expressed in haematopoietic cells. To examine the signal transduction events activated by this protein, we measured the effect of T/P on activation of the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) in mouse bone marrow-derived Ba/F3 cells. Significant increase in the activity of JNK/SAPK1 was observed in transient transfection as well as in Ba/F3 cells stably expressing T/P. This activation was abrogated when the T/P-expressing cells were treated with a specific inhibitor of the PDGFR beta tyrosine kinase, indicating that the activity of the PDGFR beta part of the fusion protein was involved in JNK/SAPK activation. Expression of a dominant negative mutant of mitogen-activated protein kinase kinase 4 (MKK4), a direct activator of JNK/SAPK, prevented T/P-induced JNK/SAPK activation. In addition, inhibition of phosphoinositide-3 OH kinase (PI-3 kinase), a promoting survival factor, potentiated the effect of T/P on JNK/SAPK activation. Interestingly, expression of T/P was shown to initiate an apoptotic response that was enhanced by treatment of cells with the PI-3 kinase inhibitor LY294002, suggesting that T/P mediated cell death through activation of JNK/SAPK signalling pathway. Consistent with this hypothesis, expression of the dominant negative mutant of MKK4 decreased T/P-mediated apoptosis, while a dominant-negative mutant of PI-3 kinase enhances cell death. These findings indicate that activation of JNK/SAPK by T/P is related to apoptosis rather than cell proliferation and transformation.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Apoptosis / genetics
-
Apoptosis / physiology*
-
Calcium-Calmodulin-Dependent Protein Kinases / physiology*
-
Cell Line
-
Chromones / pharmacology
-
Enzyme Activation
-
Enzyme Inhibitors / pharmacology
-
GTP Phosphohydrolases / genetics
-
GTP Phosphohydrolases / physiology
-
Hematopoietic Stem Cells / metabolism
-
Hematopoietic Stem Cells / pathology
-
JNK Mitogen-Activated Protein Kinases
-
MAP Kinase Kinase 4*
-
Mice
-
Mitogen-Activated Protein Kinase Kinases*
-
Mitogen-Activated Protein Kinases*
-
Morpholines / pharmacology
-
Oncogene Proteins, Fusion / antagonists & inhibitors
-
Oncogene Proteins, Fusion / genetics
-
Oncogene Proteins, Fusion / pharmacology*
-
Phosphatidylinositol 3-Kinases / genetics
-
Phosphatidylinositol 3-Kinases / metabolism
-
Phosphoinositide-3 Kinase Inhibitors
-
Phosphorylation
-
Protein Processing, Post-Translational
-
Protein Serine-Threonine Kinases / genetics
-
Protein Serine-Threonine Kinases / metabolism
-
Protein-Tyrosine Kinases / genetics
-
Protein-Tyrosine Kinases / metabolism
-
Recombinant Fusion Proteins / antagonists & inhibitors
-
Recombinant Fusion Proteins / physiology
-
Signal Transduction / physiology*
-
Transfection
Substances
-
Chromones
-
Enzyme Inhibitors
-
Morpholines
-
Oncogene Proteins, Fusion
-
Phosphoinositide-3 Kinase Inhibitors
-
Recombinant Fusion Proteins
-
TEL-PDGFRbeta fusion protein, human
-
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
-
Protein-Tyrosine Kinases
-
Protein Serine-Threonine Kinases
-
Calcium-Calmodulin-Dependent Protein Kinases
-
JNK Mitogen-Activated Protein Kinases
-
Mitogen-Activated Protein Kinases
-
MAP Kinase Kinase 4
-
MAP2K4 protein, human
-
Map2k4 protein, mouse
-
Mitogen-Activated Protein Kinase Kinases
-
GTP Phosphohydrolases